norfloxacin has been researched along with Chronic Kidney Failure in 10 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pefloxacin was used as monotherapy in 15 cases of peritonitis occurring in patients undergoing continuous ambulatory peritoneal dialysis (CAPD)." | 7.67 | [Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ( Benevent, D; Denis, F; Lagarde, C; Mounier, M, 1987) |
| "Pefloxacin was used as monotherapy in 15 cases of peritonitis occurring in patients undergoing continuous ambulatory peritoneal dialysis (CAPD)." | 3.67 | [Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ( Benevent, D; Denis, F; Lagarde, C; Mounier, M, 1987) |
| " For the other new quinolones, a decrease in glomerular filtration rate below 20-30 ml/min induces an increase in terminal half-life and a decrease in plasma and renal clearance, related to the degree of renal impairment." | 2.38 | Pharmacokinetics of quinolones in renal insufficiency. ( Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990) |
| " The mean serum elimination half-life was 8." | 1.27 | [Human and animal studies on the pharmacokinetics of norfloxacin in renal failure]. ( Akaba, K; Irikura, T; Kusajima, H; Miyahara, T; Saito, A; Shimada, J; Uchida, H, 1986) |
| " The mean apparent elimination half-life was 13." | 1.27 | Pharmacokinetics of pefloxacin in renal insufficiency. ( Bariety, J; Cunci, R; Jacquot, C; Montay, G, 1985) |
| "Norfloxacin is an antibacterial drug chiefly eliminated by the kidney and therefore useful in the treatment of urinary tract infections." | 1.27 | Pharmacokinetics of norfloxacin in chronic renal failure. ( Arrigo, G; Broccali, G; Cavaliere, G; D'Amico, G; Passarella, E, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (60.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eandi, M | 1 |
| Viano, I | 1 |
| Di Nola, F | 1 |
| Leone, L | 1 |
| Genazzani, E | 1 |
| Pascual, J | 1 |
| Orofino, L | 1 |
| Hernández, E | 1 |
| Liaño, F | 1 |
| García-González, R | 1 |
| Ortunño, J | 1 |
| Roy, A | 1 |
| Kalita, J | 1 |
| Gayathri, N | 1 |
| Shankar, SK | 1 |
| Misra, UK | 1 |
| Abad, A | 1 |
| López, P | 1 |
| Bauza, J | 1 |
| Fillastre, JP | 1 |
| Leroy, A | 1 |
| Moulin, B | 1 |
| Dhib, M | 1 |
| Borsa-Lebas, F | 1 |
| Humbert, G | 1 |
| Denis, F | 1 |
| Mounier, M | 1 |
| Lagarde, C | 1 |
| Benevent, D | 1 |
| Di Veroli, C | 1 |
| Carlizzi, G | 1 |
| Xagoraris, V | 1 |
| Shimada, J | 1 |
| Saito, A | 1 |
| Akaba, K | 1 |
| Miyahara, T | 1 |
| Kusajima, H | 1 |
| Uchida, H | 1 |
| Irikura, T | 1 |
| Montay, G | 1 |
| Jacquot, C | 1 |
| Bariety, J | 1 |
| Cunci, R | 1 |
| Arrigo, G | 1 |
| Cavaliere, G | 1 |
| D'Amico, G | 1 |
| Passarella, E | 1 |
| Broccali, G | 1 |
1 review available for norfloxacin and Chronic Kidney Failure
| Article | Year |
|---|---|
Pharmacokinetics of quinolones in renal insufficiency.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Glomerular Filtration | 1990 |
9 other studies available for norfloxacin and Chronic Kidney Failure
| Article | Year |
|---|---|
Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.
Topics: Adult; Aged; Anti-Infective Agents; Female; Hepatitis B; Humans; Kidney Failure, Chronic; Kinetics; | 1983 |
Subacute thyroiditis in a renal allograft recipient.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Biopsy, Needle; Cyclosporine; Escherichia coli Infe | 1996 |
Reversible neuropathy in chronic renal failure.
Topics: Axons; Demyelinating Diseases; Humans; Kidney Failure, Chronic; Male; Middle Aged; Motor Neuron Dise | 1998 |
Norfloxacin-induced positive direct antiglobulin test.
Topics: Adsorption; Aged; Anti-Infective Agents; Antibodies; Coombs Test; Erythrocytes; False Positive React | 1999 |
[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics].
Topics: Adult; Aged; Anti-Infective Agents; Drug Tolerance; Humans; Kidney Failure, Chronic; Middle Aged; No | 1987 |
[Norfloxacin in chronic renal insufficiency].
Topics: Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Norfloxacin; Urinary Tract Infections | 1987 |
[Human and animal studies on the pharmacokinetics of norfloxacin in renal failure].
Topics: Administration, Oral; Adult; Aged; Animals; Bile; Female; Half-Life; Humans; Injections, Intravenous | 1986 |
Pharmacokinetics of pefloxacin in renal insufficiency.
Topics: Adult; Aged; Anti-Infective Agents; Half-Life; Humans; Kidney Failure, Chronic; Kinetics; Male; Midd | 1985 |
Pharmacokinetics of norfloxacin in chronic renal failure.
Topics: Adolescent; Adult; Biological Availability; Female; Half-Life; Humans; Kidney; Kidney Failure, Chron | 1985 |